AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 127.04 No Change ▼ 0.00 (0%)
BOP 6.67 No Change ▼ 0.00 (0%)
CNERGY 4.51 No Change ▼ 0.00 (0%)
DCL 8.55 No Change ▼ 0.00 (0%)
DFML 41.44 No Change ▼ 0.00 (0%)
DGKC 86.85 No Change ▼ 0.00 (0%)
FCCL 32.28 No Change ▼ 0.00 (0%)
FFBL 64.80 No Change ▼ 0.00 (0%)
FFL 10.25 No Change ▼ 0.00 (0%)
HUBC 109.57 No Change ▼ 0.00 (0%)
HUMNL 14.68 No Change ▼ 0.00 (0%)
KEL 5.05 No Change ▼ 0.00 (0%)
KOSM 7.46 No Change ▼ 0.00 (0%)
MLCF 41.38 No Change ▼ 0.00 (0%)
NBP 60.41 No Change ▼ 0.00 (0%)
OGDC 190.10 No Change ▼ 0.00 (0%)
PAEL 27.83 No Change ▼ 0.00 (0%)
PIBTL 7.83 No Change ▼ 0.00 (0%)
PPL 150.06 No Change ▼ 0.00 (0%)
PRL 26.88 No Change ▼ 0.00 (0%)
PTC 16.07 No Change ▼ 0.00 (0%)
SEARL 86.00 No Change ▼ 0.00 (0%)
TELE 7.71 No Change ▼ 0.00 (0%)
TOMCL 35.41 No Change ▼ 0.00 (0%)
TPLP 8.12 No Change ▼ 0.00 (0%)
TREET 16.41 No Change ▼ 0.00 (0%)
TRG 53.29 No Change ▼ 0.00 (0%)
UNITY 26.16 No Change ▼ 0.00 (0%)
WTL 1.26 No Change ▼ 0.00 (0%)
BR100 10,010 Increased By 126.5 (1.28%)
BR30 31,023 Increased By 422.5 (1.38%)
KSE100 94,192 Increased By 836.5 (0.9%)
KSE30 29,201 Increased By 270.2 (0.93%)
Editorials

Renowned cancer-fighting protein can also boost cancer growth: study

A new study has challenged the fact that a widely known human protein that was previously thought to help fight can
Published February 2, 2019 Updated February 7, 2019

A new study has challenged the fact that a widely known human protein that was previously thought to help fight cancer can even boost the tumor growth too.

Scientists from University of California San Diego have carried out a new study challenging the description of the human protein ‘p53’ that is renowned for its cancer-fighting abilities, leading to its popular title as ‘the guardian of the genome’.

“The widely accepted idea is that p53 suppresses cancer, but in our study we would argue against that. In some cancers it would have the opposite effect by promoting cancer,” said researcher Yang Xu.

Smart cancer pills track patients with tiny sensors in their medicines

Studying the ‘wild type’ version of p53 – WTp53 – that is present widely in nature, the team found evidences that in some cases, the protein instead promotes tumors rather than suppressing them. The finding explains the established enigma that though p53 is mutated in over 50% of all human cancers, it is not frequently mutated in some cancers such as liver cancer.

Over four years research on liver cancer showed that WTp53 stimulates tumor growth by enhancing cancer metabolism. The key, as the researchers explain, is a protein called PUMA, which works inside the energy hub of cells – the mitochondria.

They found that at appropriate levels, PUMA disrupts normal function of mitochondria and causes a switch from oxidative phosphorylation – process for efficient energy production in cells – to glycolysis – alternative energy path that helps boost cancer metabolism.

“It’s actually the same function but playing exactly the opposite role in two different contexts,” said Xu publishing their study in the journal Cancer Cell.

Xu notified that the research provides a warning for cancer drug discovery. Drug therapies designed to improve p53’s function in cancer patient might be inadvertently causing an opposite effect, wrote Science Daily.

Copyright Business Recorder, 2019

Comments

Comments are closed.